Hepatitis Test Solution/Diagnosis Market
The global hepatitis test solution/diagnosis market is valued at 2.54 billion in 2017 and expected to grow at CAGR of 4.9% to USD 3.37 billion by 2023 during the forecast period.
This market is primarily driven by factors such as the high burden of hepatitis worldwide, increasing number of blood transfusions and donations, benefits offered by PoC instruments & kits, and awareness initiatives
The ELISA segment is expected to account for the largest share of the global hepatitis test solution/diagnosis market, by technology. The large share of ELISA is mainly driven by the wide acceptance of this test in clinical practices to diagnose hepatitis.
North America is expected to account for the largest share of the global hepatitis test solution/diagnosis market. The large share of the North America region is mainly attributed to factors such as the developed healthcare systems in the US and Canada, rising adoption of advanced technologies, and the presence of a large number of leading national clinical laboratories.
The key players in the hepatitis test solution/diagnosis market are Roche (Switzerland), Abbott Laboratories (US), Bio-Rad (US), Siemens (Germany), DiaSorin (Italy), QIAGEN (Netherlands), Danaher (US), bioMérieux (France), and Grifols (Spain).
Hepatitis test solution/diagnosis Market, by Disease type
Other Disease type
Hepatitis test solution/diagnosis Market, by Technology
Rapid Diagnostics test
Hepatitis test solution/diagnosis Market, by End User
Hospitals & Diagnostics Labs
Other end user
Every order comes with Analyst Support.
We offer customization to cater your needs to fullest.
We value integrity, quality and authenticity the most.